Sitemap - 2023 - The Drug Development Letter
CAR T cells linked to secondary AML/MDS
Observational studies and randomized trials
HLA-based therapeutics: an entire drug pipeline is based on a patient’s race.
How to read and interpret Kaplan Meier Curves
Giving adjuvant Xeloda to Biliary cancer was and is crazy
Anticoagulating people forever after unprovoked VTE lacks robust evidence
How much money do we waste when cancer patients change dose and throw out their pills?
ADAURA trial: An Unethical Trial
Treatment After Progression in Oncology Studies is Vitally Important
How to read and interpret a cancer clinical trial
Abbvie voluntarily recalls Ibrutinib in MCL and MZL
Can altering the microbiome improve how checkpoint inhibitors work?
Tumor Agnostic Drugs are Not Tumor Agnostic: An Analysis of Response Rate by Tumor Type
Real World Evidence - Danish Keynote Slides
Zuma 7 - crossover rate confirmed
Zuma 7 has OS benefit... Not so fast.
The starting dose is fair, but that is about it
Relapsed cancer patients die so asymptomatic pre-cancer patients can go on trial
Which Drugs is Medicare Expected to Negotiate?
More on Randomized Trials - Equivalence/ NI/ S, P values, control arms, crossover
Dostarlimab in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer: The Next Magic Bullet?
Randomized trials - the basics
How to search for, negotiate, and choose your first job
PSMA pet scans: Just because it is more sensitive doesn't make it better